Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 13 Φεβ 2020 · MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis.

    • Table 2

      Knock-out: substitution of 1485 bp of exon 2 and exon 3 by...

    • Hunter Syndrome

      MPS II is the most prevalent MPS in East Asian regions,...

  2. 18 Σεπ 2018 · In Malaysia, diagnosis and treatment of patients with mucopolysaccharidoses (MPS) is mainly localized at Hospital Kuala Lumpur, which is the national referral center for rare diseases.

  3. 3 Αυγ 2020 · Mucopolysaccharidosis, type II (MPS II, MIM 309900) is a severe lysosomal storage disease with multisystem involvement. There is one product approved by the FDA, an enzyme replacement...

  4. 7 Νοε 2011 · Mucopolysaccharidosis type II (MPS II) is a rare, life-limiting, X-linked recessive disease characterised by deficiency of the lysosomal enzyme iduronate-2-sulfatase. Consequent accumulation of glycosaminoglycans leads to pathological changes in multiple body systems.

  5. The Editors and the Malaysian Pharmaceutical Society welcome papers for publication in the Malaysian Journal of Pharmacy. This peer-reviewed journal covers areas related to Pharmacy in the form of Short Communication, Original Research Article, Case Study, Reviews, and Book.

  6. The Editors and the Malaysian Pharmaceutical Society welcome papers for publication in the Malaysian Journal of Pharmacy. This nationally peer-reviewed journal covers areas related to Pharmacy in the form of General articles, Reviews, Research papers and Book Reviews.

  7. The Malaysian Journal of Pharmacy is a bi-annual publication of the Malaysian Pharmaceutical Society. Enquiries are to be directed to the Publisher at the above address or the Editor-in-Chief at the Pharmacy Department, Faculty of Allied Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 53100 Kuala Lumpur.